Zoetis (NYSE:ZTS) Sets New 12-Month Low – Should You Sell?

Zoetis Inc. (NYSE:ZTS)’s share price reached a new 52-week low on Wednesday. The stock traded as low as $69.52 and last traded at $69.7640, with a volume of 2517368 shares changing hands. The stock had previously closed at $70.30.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ZTS. TD Cowen lowered their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. Morgan Stanley set a $85.00 price objective on shares of Zoetis in a research report on Friday, August 7th. Barclays cut their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. William Blair restated a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, HSBC decreased their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $101.08.

Zoetis Stock Performance

The firm’s 50-day moving average price is $74.51 and its 200 day moving average price is $86.56. The company has a market cap of $28.54 billion, a price-to-earnings ratio of 11.38, a PEG ratio of 1.63 and a beta of 0.75. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue was down .2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. State Street Corp increased its stake in shares of Zoetis by 1.8% in the second quarter. State Street Corp now owns 19,667,723 shares of the company’s stock valued at $1,413,323,000 after buying an additional 343,322 shares during the period. Tidal Investments LLC boosted its holdings in shares of Zoetis by 22.8% in the second quarter. Tidal Investments LLC now owns 493,507 shares of the company’s stock worth $35,463,000 after acquiring an additional 91,492 shares during the period. National Pension Service raised its position in shares of Zoetis by 9.6% in the second quarter. National Pension Service now owns 839,875 shares of the company’s stock worth $60,353,000 after buying an additional 73,785 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of Zoetis in the second quarter worth approximately $223,000. Finally, Engineers Gate Manager LP lifted its stake in Zoetis by 3,551.3% during the second quarter. Engineers Gate Manager LP now owns 107,678 shares of the company’s stock worth $7,738,000 after purchasing an additional 104,729 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.